Biotalys Nv · EURONEXT:BTLS
Biotalys Nv — FY2024 Earnings Presentation
13 slides from Biotalys Nv's earnings presentation, Mar 19, 2025
Slide 1: FY 2024 Results and Highlights
Investor Webcast FY 2024 Results and Highlights 19 March 2025 1
Slide 2: Your speakers today
Your speakers today Kevin Helash Douglas Minder Chief Executive Officer Chief Finance Officer 2
Slide 3: Disclaimer
Disclaimer This presentation, including the oral presentation (together, the “Materials”) has been prepared by the management of Biotalys NV (the “Company”). The Materials must be treated confidentially and may not be distributed, passed on or otherwise disclosed. The Materials serve information pur
Slide 4: 2024 highlights
2024 highlights • EVOCA • Pipeline • People • Finance • Mission 4
Slide 5: Kevin Helash, CEO
¥ biotalys Kevin Helash, CEO
Slide 6: Looking ahead to 2025
Looking ahead to 2025 • 4 key initiatives: • Securing regulatory approvals • Expanding our pipeline • Working towards commercialization of our portfolio • Maintaining strict financial discipline 6
Slide 7: Regulatory approval process continues to advance
Regulatory approval process continues to advance Regulatory packages filed in US and EU; 1st phase in EU finalized with favorable advice from NL regulator Novel nature of the technology requires in-depth review, but also sets standard for future approvals of protein-based biocontrols Ongoing dialogu
Slide 8: Innovative pipeline of biofungicides and bioinsecticides
Innovative pipeline of biofungicides and bioinsecticides Global Market Partnership Program Target Market Discovery Development Registration Size Agreement EVOCA Botrytis, powdery High-value fruits & Pilot product 1st Gen mildew vegetables EVOCA Botrytis, powdery High-value fruits & $2.4B Next Gen mi
Slide 9: Strict financial discipline
Strict financial discipline Biotalys will maximise the impact of its time, equipment, investments, and cash to support its most critical initiatives Resources
Slide 10: Douglas Minder, CFO
Douglas Minder, CFO ed, . ¥ biotalys 10
Slide 11: Key financials – FY 2024
Key financials – FY 2024 In € thousand December 31, 2024 December 31, 2023 Other operating income 3,183 2,611 Research and development expenses (10,959) (16,608) General and administration expenses (5,716) (6,894) Operating loss (13,492) (20,891) Loss of the period (13,188) (20,510) Basic and dilute
Slide 12: Conclusion and Q&A
Conclusion and Q&A Kevin Helash Douglas Minder Chief Executive Officer Chief Finance Officer 12
Slide 13: ¥, biotalys
PA : ¥, biotalys